Best Revascularization Strategy in Patients with Left Ventricular Deterioration

Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy. 

La mejor revascularización en pacientes con deterioro del ventrículo izquierdo

According to this recent analysis of the SCAAR registry published in the European Heart Journal, long term followup seems to justify taking a higher risk initially, higher risk being myocardial revascularization surgery (CABG).

The study looked at all cause death in patients receiving CABG vs PCI presenting cardiac failure due to ventricular function deterioration and multivessel disease (>50% angiographic lesion in at least 2 vessels or in left main).

Propensity score was used to compare populations, which resulted in a total of 2509 patients; 35.8% presented diabetes and a similar percentage had prior MI history. Mean age was 68.1 ± 9.4 years with nearly half the population over 70, and most had lesions in 3 vessels or in the left main. 

Patients were initially treated with PCI (56.2%) and surgery (43.8% of the population). 


Read also: The Role of Aspirin after the TWILIGHT-ACS.


After mean followup of four years (some reached 10) mortality resulted lower in the surgery group (OR 0.62; CI 95% 0.41 to 0.96; p=0.031). However, this increased linearly in centers where PCI was the preferred revascularization strategy. 

Conclusion

In the long term, patients with ischemic heart failure will benefit from the surgical revascularization strategy. 

ehab273

Original Title: Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Reference: Sebastian Völz et al. European Heart Journal (2021) 42, 2657–2664 doi:10.1093/eurheartj/ehab273.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...